Document Detail


Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
MedLine Citation:
PMID:  21219297     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Heat shock protein 90 (HSP90) is a molecular chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell cycle control and proliferative/anti-apoptotic signalling. HSP90 is overexpressed in a range of cancers, and may contribute to tumour cell survival by stabilizing aberrant signalling proteins and by interfering with apoptosis. Tanespimycin, an HSP90 inhibitor, reduces tumour cell survival in vitro. In multiple myeloma (MM), HSP90 inhibition affects multiple client proteins that contribute to tumour cell survival, including the IGF1 receptor and the IL-6 receptor, and elements of the PI3/Akt, STAT3, and MAPK signalling pathways. HSP90 inhibition also abrogates the protective effect of bone marrow stromal cells and inhibits angiogenesis and osteoclastogenesis. Tanespimycin acts synergistically with the proteasome inhibitor bortezomib in MM cells and tumour explants, possibly reducing their ability to resist bortezomib-induced stress to the endoplasmic reticulum. The combination of tanespimycin and bortezomib has demonstrated significant and durable responses with acceptable toxicity in a phase I/II study in patients with relapsed and relapsed/refractory MM. HSP90 inhibition is a promising strategy in MM especially in combination with bortezomib; additional studies will further evaluate optimal dosings of candidate drugs and schedules, as well as confirm efficacy in comparative phase III trials.
Authors:
Paul G Richardson; Constantine S Mitsiades; Jacob P Laubach; Sagar Lonial; Asher A Chanan-Khan; Kenneth C Anderson
Related Documents :
11890677 - Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate ...
21526377 - Delayed treatment with vitamin c and n-acetyl-l: -cysteine protects schwann cells witho...
14698567 - Epigallocatechin 3-gallate attenuates neuronal damage induced by 3-hydroxykynurenine.
20507447 - Expression of barley bax inhibitor-1 in carrots confers resistance to botrytis cinerea.
20661717 - Silencing of cytosolic nadp(+)-dependent isocitrate dehydrogenase gene enhances ethanol...
22723347 - Differentiated embryo-chondrocyte expressed gene 1 regulates p53-dependent cell surviva...
Publication Detail:
Type:  Journal Article     Date:  2011-01-10
Journal Detail:
Title:  British journal of haematology     Volume:  152     ISSN:  1365-2141     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  367-79     Citation Subset:  IM    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Affiliation:
Dana-Farber Cancer Institute, Boston, MA Emory University, The Winship Cancer Institute, Atlanta, GA Roswell Park Cancer Institute, Buffalo, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomize...
Next Document:  Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essent...